Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 205 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: levonorgestrel Clear all

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Oral contraceptive, Acetaminophen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
Interventions: TFV/LNG IVR, Placebo; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Healthy
Interventions: PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Pregnancy
Interventions: Copper T380 IUD, levonorgestrel; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: West Valley City, Utah

Conditions: Healthy Participants
Interventions: AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
Interventions: Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program; Drug · Device · Behavioral
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 4
States / cities: Houston, Texas

Conditions: Contraception
Interventions: DMPA, oral contraceptives, Implanon®, ParaGard®, Mirena®; Drug
Lead sponsor: FHI 360; Other
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 916 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Post Partum
Interventions: Plan B (Levonorgestrel); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 14 Years to 19 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Contraception, Body Weight
Interventions: ECx1, ECx2; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Prevention
Interventions: 200 mg of DPV + 320 mg LNG, 200 mg of DPV; Combination Product
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Bariatric Surgery, Sleeve Gastrectomy, Obesity
Interventions: Dietary habits plan; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Years to 62 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
Interventions: Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Healthy Volunteer
Interventions: ABBV-295, Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Contraception
Interventions: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer); Device
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 16 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Healthy
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions: Levonorgestrel Intrauterine System, Norethindrone Acetate; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 10 Years to 24 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, LNG/EE; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Primary Dysmenorrhea
Interventions: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova), Placebo Match to SH T00658ID, Placebo Match to SH D593B; Drug
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 50 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Tucson, Arizona • San Diego, California • Hialeah, Florida + 7 more

Conditions: Menopause, Healthy Female Participants
Interventions: Estradiol/Levonorgestrel Transdermal System; Drug
Lead sponsor: Corium Innovations, Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Contraception
Interventions: Emergency contraception website, Emergency contraception video; Other
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception
Interventions: Copper T-380 IUD, LNG IUD, Contraceptive implant Nexplanon, Depo-Provera; Drug · Device
Lead sponsor: University of Utah; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: West Valley City, Utah

Conditions: Contraception
Interventions: Levonorgestrel IUS; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contraception, Postpartum Period
Interventions: LNG-IUS; Device
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Little Rock, Arkansas • Portsmouth, Virginia

Conditions: IUD, IUD Insertion Complication, IUD; Complications
Interventions: Sound sparing levonorgestrel 52 mg IUD placement; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer

Long-Acting Reversible Contraception

Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens

Emergency Contraception and Body Weight: Pilot Study

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

Role of Dietary Habits in Efficacy of Bariatric Surgery - Study C

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Effect on Primary Dysmenorrhea

A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects

Targeted Video Messaging About Emergency Contraception

Quick Start of Highly Effective Contraception

Early Postpartum Intrauterine Device (IUD) Placement

A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period

IUD Placement Without Sounding